AnalystsBrian SkorneyBrian Skorney's Stock Forecasts
AnalystsBrian Skorney
Analyst Ranking
Top 14%
#602 out of 4560 analysts
Average Return
+13.29%
Win Rate
53%27 out of 51
Risk vs Reward
Poor
Good
Brian Skorney's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Applied Therapeutics IncAPLT | +231.85% | $1.34 | $4.46 | 2023-04-25 - 2024-04-23 | Buy |
Crinetics Pharmaceuticals IncCRNX | +195.52% | $15.84 | $46.81 | 2023-03-30 - 2024-03-28 | Buy |
Albireo Pharma IncALBO | +144.19% | $18.08 | $44.15 | 2022-08-16 - 2023-03-02 | Buy |
Intercept Pharmaceuticals IncICPT | +99.37% | $9.53 | $19.00 | 2023-05-22 - 2023-11-07 | Buy |
Albireo Pharma IncALBO | +98.61% | $22.23 | $44.15 | 2022-10-12 - 2023-03-02 | Buy |
Brian Skorney Analyst Color
Get additional color on Brian Skorney's coverage of popular stocks
Brian Skorney's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Marinus Pharmaceuticals IncMRNS | 4 | Hold | $2.00 | +38.89% | Downgrades | 9 days ago |
Regenxbio IncRGNX | 3 | Buy | $39.00 | +145.28% | Maintains | 2 months ago |
Crinetics Pharmaceuticals IncCRNX | 3 | Buy | $52.00 | +17.59% | Maintains | 2 months ago |
Alto Neuroscience IncANRO | 1 | Buy | $32.00 | +130.55% | Initiates Coverage On | 2 months ago |
Biogen IncBIIB | 6 | Buy | $316.00 | +63.58% | Maintains | 2 months ago |
Biohaven LtdBHVN | 1 | Buy | $58.00 | +46.43% | Initiates Coverage On | 5 months ago |
Xenon Pharmaceuticals IncXENE | 1 | Buy | $63.00 | +53.32% | Initiates Coverage On | 5 months ago |
Neurocrine Biosciences IncNBIX | 3 | Buy | $148.00 | +5.65% | Maintains | 9 months ago |
Reata Pharmaceuticals IncRETA | 6 | Buy | $173.00 | +0.37% | Maintains | 9 months ago |
Eiger Biopharmaceuticals IncEIGRQ | 1 | Buy | $150.00 | +8,595.65% | Maintains | 10 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Hold | $760.00 | -16.24% | Maintains | 10 months ago |
Intercept Pharmaceuticals IncICPT | 3 | Buy | $18.00 | -5.26% | Maintains | a year ago |
Vertex Pharmaceuticals IncVRTX | 13 | Hold | $325.00 | -19.74% | Maintains | a year ago |
Applied Therapeutics IncAPLT | 2 | Buy | $14.00 | +213.90% | Maintains | a year ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $202.00 | N/A | Maintains | a year ago |
Myovant Sciences LtdMYOV | 1 | Hold | $27.00 | N/A | Downgrades | 2 years ago |
Albireo Pharma IncALBO | 4 | Buy | $55.00 | N/A | Maintains | 2 years ago |
Enanta Pharmaceuticals IncENTA | 3 | Buy | $90.00 | N/A | Maintains | 2 years ago |
Reneo Pharmaceuticals IncRPHM | 1 | Buy | $28.00 | N/A | Initiates Coverage On | 2 years ago |
Immunovant IncIMVT | 1 | Hold | $10.00 | N/A | Downgrades | 3 years ago |
Vistagen Therapeutics IncVTGN | 1 | Buy | $270.00 | N/A | Initiates Coverage On | 3 years ago |
Voyager Therapeutics IncVYGR | 1 | Hold | $6.00 | N/A | Downgrades | 3 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Principia Biopharma IncPRNB | 1 | Buy | $78.00 | N/A | Maintains | 4 years ago |
Amgen IncAMGN | 2 | Sell | $185.00 | N/A | Downgrades | 4 years ago |
Celgene CorpCELG | 2 | Buy | $92.00 | N/A | Upgrades | 5 years ago |
Curis IncCRIS | 3 | Buy | $300.00 | N/A | Maintains | 6 years ago |
Ablynx NvABLX | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Beigene LtdBGNE | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Cempra IncCEMP | 1 | Hold | N/A | N/A | Upgrades | 6 years ago |
Achillion Pharmaceuticals IncACHN | 1 | Hold | N/A | N/A | Downgrades | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.